Guggenheim Reiterates a Buy Rating on AbbVie (ABBV), Sets a PT of $227

AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy right now. In a report released on September 11, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV), setting a price target of $227.00.

AbbVie (ABBV)'s Dividend Track Record: How It Became a Leader in Consistent Dividends

In its fiscal Q2 2025 results, AbbVie Inc. (NYSE:ABBV) reported a diluted EPS of $0.52 on a GAAP basis, reflecting a decrease of 32.5%. Adjusted diluted EPS for the quarter reached $2.97, up 12.1%. Management reported that the results included an “unfavorable impact of $0.42 per share.”

Furthermore, AbbVie Inc. (NYSE:ABBV) delivered net revenues of $15.423 billion in fiscal Q2 2025, up 6.6% on a reported basis or 6.5% on an operational basis.

AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.